A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus

Journal of Virology

Volumn 88, Issue 21, 2014, Pages 12222-12232

  Nunes, Sandro Filipe ^a   Hamers, Claude ^b   Ratinier, Maxime ^a   Shaw, Andrew ^a   Brunet, Sylvie ^b   Hudelet, Pascal ^b   Palmarini, Massimo ^a  

^a MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLUETONGUE VIRUS VACCINE; LIVE VACCINE; PROTEIN VP2; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ARTICLE; BLUETONGUE; BLUETONGUE ORBIVIRUS; CONTROLLED STUDY; GENETIC MANIPULATION; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE GENETICS; SYNTHETIC BIOLOGY; VACCINATION; VACCINE PRODUCTION; VIRUS IDENTIFICATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; BLOOD; GENETIC REASSORTMENT; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; SERODIAGNOSIS; SEROTYPE; SHEEP;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BLUETONGUE; BLUETONGUE VIRUS; NEUTRALIZATION TESTS; REASSORTANT VIRUSES; SEROGROUP; SHEEP; SYNTHETIC BIOLOGY; VIRAL VACCINES;

EID: 84907986010     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02183-14     Document Type: Article

References (53)

1. Mellor PS, Baylis M, Mertens PP. 2009. Bluetongue. Academic Press, London, United Kingdom.
2. Caporale M, Di Gialleonorado L, Janowicz A, Wilkie G, Shaw A, Savini G, Van Rijn PA, Mertens P, Di Ventura M, Palmarini M. 2014. Virus and host factors affecting the clinical outcome of bluetongue virus infection. J. Virol. 88:10399-10411. http://dx.doi.org/10.1128/JVI.01641-14.
3. Belhouchet M, Mohd Jaafar F, Firth AE, Grimes JM, Mertens PP, Attoui H. 2011. Detection of a fourth orbivirus nonstructural protein. PLoS One 6:e25697. http://dx.doi.org/10.1371/journal.pone.0025697.
4. Ratinier M, Caporale M, Golder M, Franzoni G, Allan K, Nunes SF, Armezzani A, Bayoumy A, Rixon F, Shaw A, Palmarini M. 2011. Identification and characterization of a novel nonstructural protein of bluetongue virus. PLoS Pathog. 7:e1002477. http://dx.doi.org/10.1371 /journal.ppat.1002477.
5. Roy P. 2008. Functional mapping of bluetongue virus proteins and their interactions with host proteins during virus replication. Cell Biochem. Biophys. 50:143-157. http://dx.doi.org/10.1007/s12013-008-9009-4.
6. Gouet P, Diprose JM, Grimes JM, Malby R, Burroughs JN, Zientara S, Stuart DI, Mertens PP. 1999. The highly ordered double-stranded RNA genome of bluetongue virus revealed by crystallography. Cell 97:481-490. http://dx.doi.org/10.1016/S0092-8674(00)80758-8.
7. Patel A, Roy P. 2014. The molecular biology of Bluetongue virus replication. Virus Res. 182:5-20. http://dx.doi.org/10.1016/j.virusres.2013.12.017.
8. Kahlon J, Sugiyama K, Roy P. 1983. Molecular basis of bluetongue virus neutralization. J. Virol. 48:627-632.
9. Huismans H, Erasmus BJ. 1981. Identification of the serotype-specific and group-specific antigens of bluetongue virus. Onderstepoort J. Vet. Res. 48:51-58.
10. Hofmann MA, Renzullo S, Mader M, Chaignat V, Worwa G, Thuer B. 2008 Genetic characterization of Toggenburg orbivirus, a new bluetongue virus, from goats, Switzerland. Emerg. Infect. Dis. 14:1855-1861. http://dx.doi.org/10.3201/eid1412.080818.
11. Maan S, Maan NS, Nomikou K, Veronesi E, Bachanek-Bankowska K, Belaganahalli MN, Attoui H, Mertens PP. 2011. Complete genome characterisation of a novel 26th bluetongue virus serotype from Kuwait. PLoS One 6:e26147. http://dx.doi.org/10.1371/journal.pone.0026147.
12. Maan S, Maan NS, Samuel AR, Rao S, Attoui H, Mertens PP. 2007. Analysis and phylogenetic comparisons of full-length VP2 genes of the 24 bluetongue virus serotypes. J. Gen. Virol. 88:621-630. http://dx.doi.org /10.1099/vir.0.82456-0.
13. Shaw AE, Ratinier M, Nunes SF, Nomikou K, Caporale M, Golder M, Allan K, Hamers C, Hudelet P, Zientara S, Breard E, Mertens P, Palmarini M. 2013. Reassortment between two serologically unrelated bluetongue virus strains is flexible and can involve any genome segment. J. Virol. 87:543-557. http://dx.doi.org/10.1128/JVI.02266-12.
14. Zhang X, Boyce M, Bhattacharya B, Schein S, Roy P, Zhou ZH. 2010. Bluetongue virus coat protein VP2 contains sialic acid-binding domains, and VP5 resembles enveloped virus fusion proteins. Proc. Natl. Acad. Sci. U. S. A. 107:6292-6297. http://dx.doi.org/10.1073/pnas.0913403107.
15. Erasmus BJ. 1975. Bluetongue in sheep and goats. Aust. Vet. J. 51:165-170 http://dx.doi.org/10.1111/j.1751-0813.1975.tb00048.x.
16. MacLachlan NJ, Crafford JE, Vernau W, Gardner IA, Goddard A, Guthrie AJ, Venter EH. 2008. Experimental reproduction of severe bluetongue in sheep. Vet. Pathol. 45:310-315. http://dx.doi.org/10.1354/vp.45-3-310.
17. Zientara S, Sanchez-Vizcaino JM. 2013. Control of bluetongue in Europe. Vet. Microbiol. 165:33-37. http://dx.doi.org/10.1016/j.vetmic.2013.01.010.
18. Savini G, MacLachlan NJ, Sanchez-Vizcaino JM, Zientara S. 2008. Vaccines against bluetongue in Europe. Comp. Immunol. Microbiol. Infect. Dis. 31:101-120. http://dx.doi.org/10.1016/j.cimid.2007.07.006.
19. Maclachlan NJ. 2011. Bluetongue: history, global epidemiology, and pathogenesis. Prev. Vet. Med. 102:107-111. http://dx.doi.org/10.1016/j.prevetmed.2011.04.005.
20. Wilson AJ, Mellor PS. 2009. Bluetongue in Europe: past, present and future. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364:2669-2681. http://dx.doi.org/10.1098/rstb.2009.0091.
21. Purse BV, Brown HE, Harrup L, Mertens PP, Rogers DJ. 2008. Invasion of bluetongue and other orbivirus infections into Europe: the role of biological and climatic processes. Rev. Sci. Tech. 27:427-442.
22. Purse BV, Mellor PS, Rogers DJ, Samuel AR, Mertens PP, Baylis M. 2005 Climate change and the recent emergence of bluetongue in Europe. Nat. Rev. Microbiol. 3:171-181. http://dx.doi.org/10.1038/nrmicro1090.
23. Saegerman C, Berkvens D, Mellor PS. 2008. Bluetongue epidemiology in the European Union. Emerg. Infect. Dis. 14:539-544. http://dx.doi.org/10.3201/eid1404.071441.
24. Verwoerd DW. 2012. History of orbivirus research in South Africa. J. S. Afr. Vet. Assoc. 83:532. http://dx.doi.org/10.4102/jsava.v83i1.532.
25. Batten CA, Maan S, Shaw AE, Maan NS, Mertens PP. 2008. A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment. Virus Res. 137:56-63. http://dx.doi.org/10.1016/j.virusres.2008.05.016.
26. Veronesi E, Darpel KE, Hamblin C, Carpenter S, Takamatsu HH, Anthony SJ, Elliott H, Mertens PP, Mellor PS. 2010. Viraemia and clinical disease in Dorset Poll sheep following vaccination with live attenuated bluetongue virus vaccines serotypes 16 and 4. Vaccine 28:1397-1403 http://dx.doi.org/10.1016/j.vaccine.2009.10.107.
27. Savini G, Cannas A, Casaccia C, Di Gialleonardo L, Leone A, Patta C, Nicolussi P. 2010. Risk factors associated with the occurrence of undesired effects in sheep and goats after field vaccination with modified-live vaccine against bluetongue virus serotypes 2, 4, and 16. Vet. Microbiol. 146:44-50. http://dx.doi.org/10.1016/j.vetmic.2010.04.020.
28. Veronesi E, Hamblin C, Mellor PS. 2005. Live attenuated bluetongue vaccine viruses in Dorset Poll sheep, before and after passage in vector midges (Diptera: Ceratopogonidae). Vaccine 23:5509-5516. http://dx.doi.org/10.1016/j.vaccine.2005.07.039.
29. Darpel KE, Batten CA, Veronesi E, Shaw AE, Anthony S, Bachanek-Bankowska K, Kgosana L, bin-Tarif A, Carpenter S, Muller-Doblies UU, Takamatsu HH, Mellor PS, Mertens PP, Oura CA. 2007. Clinical signs and pathology shown by British sheep and cattle infected with bluetongue virus serotype 8 derived from the 2006 outbreak in northern Europe. Vet. Rec. 161:253-261. http://dx.doi.org/10.1136/vr.161.8.253.
30. Hamers C, Galleau S, Chery R, Blanchet M, Besancon L, Cariou C, Werle-Lapostolle B, Hudelet P, Goutebroze S. 2009. Use of inactivated bluetongue virus serotype 8 vaccine against virulent challenge in sheep and cattle. Vet. Rec. 165:369-373. http://dx.doi.org/10.1136/vr.165.13.369.
31. Di Emidio B, Nicolussi P, Patta C, Ronchi GF, Monaco F, Savini G, Ciarelli A, Caporale V. 2004. Efficacy and safety studies on an inactivated vaccine against bluetongue virus serotype 2. Vet. Ital. 40:640-644.
32. Szmaragd C, Wilson AJ, Carpenter S, Wood JL, Mellor PS, Gubbins S. 2010 The spread of bluetongue virus serotype 8 in Great Britain and its control by vaccination. PLoS One 5:e9353. http://dx.doi.org/10.1371 /journal.pone.0009353.
33. Baetza HJ. 2014. Eradication of bluetongue disease in Germany by vaccination. Vet. Immunol. Immunopathol. 158:116-119. http://dx.doi.org /10.1016/j.vetimm.2013.09.001.
34. OIE. 2014. Manual of diagnostic tests and vaccines for terrestrial animals. OIE, Paris, France.
35. Boyce M, Celma CC, Roy P. 2008. Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts. J. Virol. 82:8339-8348. http://dx.doi.org/10.1128/JVI.00808-08.
36. Wilson WC, Bernard KA, Israel BA, Mecham JO. 2008. Bluetongue virus serotype 17 sequence variation associated with neutralization. DNA Seq. 19:237-240.
37. DeMaula CD, Heidner HW, Rossitto PV, Pierce CM, MacLachlan NJ. 1993 Neutralization determinants of United States bluetongue virus serotype ten. Virology 195:292-296. http://dx.doi.org/10.1006/viro.1993.1377.
38. Gould AR, Eaton BT. 1990. The amino acid sequence of the outer coat protein VP2 of neutralizing monoclonal antibody-resistant, virulent and attenuated bluetongue viruses. Virus Res. 17:161-172. http://dx.doi.org /10.1016/0168-1702(90)90062-G.
39. Pierce CM, Rossitto PV, MacLachlan NJ. 1995. Homotypic and heterotypic neutralization determinants of bluetongue virus serotype 17. Virology 209:263-267. http://dx.doi.org/10.1006/viro.1995.1253.
40. Meroc E, Herr C, Verheyden B, Hooyberghs J, Houdart P, Raemaekers M, Vandenbussche F, De Clercq K, Mintiens K. 2009. Bluetongue in Belgium: episode II. Transbound. Emerg. Dis. 56:39-48. http://dx.doi.org /10.1111/j.1865-1682.2008.01063.x.
41. Calvo-Pinilla E, Castillo-Olivares J, Jabbar T, Ortego J, de la Poza F, Marin-Lopez A. 2014. Recombinant vaccines against bluetongue virus. Virus Res. 182:78-86. http://dx.doi.org/10.1016/j.virusres.2013.11.013.
42. -/-) mice from homologous lethal challenge. Vaccine 32:4059-4067. http://dx.doi.org/10.1016/j.vaccine.2014.05.056.
43. Franceschi V, Capocefalo A, Calvo-Pinilla E, Redaelli M, Mucignat-Caretta C, Mertens P, Ortego J, Donofrio G. 2011. Immunization of knockout alpha/beta interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen. Vaccine 29:3074-3082. http://dx.doi.org/10.1016/j.vaccine.2011.01.075.
44. Ma G, Eschbaumer M, Said A, Hoffmann B, Beer M, Osterrieder N. 2012 An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. PLoS One 7:e34425. http://dx.doi.org/10.1371/journal.pone.0034425.
45. Calvo-Pinilla E, de la Poza F, Gubbins S, Mertens PP, Ortego J, Castillo-Olivares J. 2014. Vaccination of mice with a modified vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation. Virus Res. 180:23-30. http://dx.doi.org/10.1016/j.virusres.2013.12.002.
46. Roy P, Bishop DH, LeBlois H, Erasmus BJ. 1994. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 12:805-811. http://dx.doi.org/10.1016 /0264-410X(94)90289-5.
47. Stewart M, Dovas CI, Chatzinasiou E, Athmaram TN, Papanastassopoulou M, Papadopoulos O, Roy P. 2012. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. Vaccine 30:2131-2139. http://dx.doi.org/10.1016/j.vaccine.2012.01.042.
48. Kochinger S, Renevey N, Hofmann MA, Zimmer G. 2014. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection. Vet. Res. 45:64. http://dx.doi.org/10.1186 /1297-9716-45-64.
49. Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, Nordgren R, Monaco F, Savini G, Gardner IA, Maclachlan NJ. 2007. Recombinant canarypox virus vaccine coexpressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25:672-678. http://dx.doi.org/10.1016/j.vaccine.2006.08.025.
50. van Gennip RG, van de Water SG, Maris-Veldhuis M, van Rijn PA. 2012 Bluetongue viruses based on modified-live vaccine serotype 6 with exchanged outer shell proteins confer full protection in sheep against virulent BTV8. PLoS One 7:e44619. http://dx.doi.org/10.1371/journal.pone.0044619.
51. Celma CC, Boyce M, van Rijn PA, Eschbaumer M, Wernike K, Hoffmann B, Beer M, Haegeman A, De Clercq K, Roy P. 2013. Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep. J. Virol. 87:9856-9864. http://dx.doi.org/10.1128 /JVI.01514-13.
52. Guindon S, Delsuc F, Dufayard JF, Gascuel O. 2009. Estimating maximum likelihood phylogenies with PhyML. Methods Mol. Biol. 537:113-137 http://dx.doi.org/10.1007/978-1-59745-251-9_6.
53. Posada D, Crandall KA. 1998. MODELTEST: testing the model of DNA substitution. Bioinformatics 14:817-818. http://dx.doi.org/10.1093 /bioinformatics/14.9.817.